The Current Ratio as of September 2024 (TTM) for MacroGenics, Inc. (MGNX) is 2.71

According to MacroGenics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.71. This represents a change of -34.30% compared to the average of 4.13 of the last 4 quarters.

MacroGenics, Inc. (MGNX) Historical Current Ratio (quarterly & annually)

How has MGNX Current Ratio performed in the past?

The mean historical Current Ratio of MacroGenics, Inc. over the last ten years is 6.64. The current 2.71 Current Ratio has changed 3.98% with respect to the historical average. Over the past ten years (40 quarters), MGNX's Current Ratio was at its highest in in the June 2016 quarter at 17.84. The Current Ratio was at its lowest in in the June 2024 quarter at 2.71.

MacroGenics, Inc. (MGNX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of MacroGenics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MacroGenics, Inc. (MGNX) Average Current Ratio

How has MGNX Current Ratio performed in the past?

The current Current Ratio of MacroGenics, Inc. (MGNX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MacroGenics, Inc. (MGNX) Current Ratio vs. Peers

How is MGNX’s Current Ratio compared to its peers?

MacroGenics, Inc.’s Current Ratio is less than Molecular Partners AG (14.58), less than Mineralys Therapeutics, Inc. (11.20), less than AN2 Therapeutics, Inc. (10.61), less than Pharvaris N.V. (18.45), less than PepGen Inc. (7.45), less than Monte Rosa Therapeutics, Inc. (6.56), less than PMV Pharmaceuticals, Inc. (19.22), less than Tyra Biosciences, Inc. (36.46), less than Century Therapeutics, Inc. (10.62), less than Kezar Life Sciences, Inc. (9.58), less than Nkarta, Inc. (15.91), less than NGM Biopharmaceuticals, Inc. (7.79), less than Day One Biopharmaceuticals, Inc. (4.09), less than Inozyme Pharma, Inc. (9.84), less than Zentalis Pharmaceuticals, Inc. (6.59), less than Syndax Pharmaceuticals, Inc. (10.50), less than Protagonist Therapeutics, Inc. (13.73), less than Edgewise Therapeutics, Inc. (30.24), less than C4 Therapeutics, Inc. (5.09), less than Cullinan Oncology, Inc. (28.87),

Build a custom stock screener for MacroGenics, Inc. (MGNX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MacroGenics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MacroGenics, Inc. (MGNX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MacroGenics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.